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Tau is a key protein in the pathogenesis of various neurodegenerative diseases, which are categorized as
tauopathies. Because the extent of tau pathologies is closely linked to that of neuronal loss and the
clinical symptoms in Alzheimer’s disease, anti-tau therapeutics, if any, could be beneﬁcial to a broad
spectrum of tauopathies. To learn more about tauopathy, we developed a novel transgenic nematode
(Caenorhabditis elegans) model that expresses either wild-type or R406W tau in all the neurons. The
wild-type tau-expressing worms exhibited uncoordinated movement (Unc) and neuritic abnormalities.
Tau accumulated in abnormal neurites that lost microtubules. Similar abnormalities were found in the
worms that expressed low levels of R406W-tau but were not in those expressing comparative levels of
wild-type tau. Biochemical studies revealed that tau is aberrantly phosphorylated but forms no
detergent-insoluble aggregates. Drug screening performed in these worms identiﬁed curcumin, a major
phytochemical compound in turmeric, as a compound that reduces not only Unc but also the neuritic
abnormalities in both wild-type and R406W tau-expressing worms. Our observations suggest that
microtubule stabilization mediates the antitoxicity effect of curcumin. Curcumin is also effective in the
worms expressing tau fragment, although it does not prevent the formation of tau-fragment dimers.
These data indicate that curcumin improves the tau-induced neuronal dysfunction that is independent of
insoluble aggregates of tau.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is themost common cause of dementia
among the elderly (Mayeux and Stern, 2012). Because of the
increasing prevalence of AD with age and rapid extension of life-
span, it is urgent to develop prevention and therapeutic strategies
against AD (Mangialasche et al., 2010). A characteristic pathological
change of AD is the formation of tau inclusions, which consist of
neuroﬁbrillary tangles and neuropil threads, in the areas of the
brain where neuronal loss occurs (Braak and Braak, 1997; Gomez-
Isla et al., 1997). It is believed that long-term Ab deposition trig-
gers the death cascade of tau, which eventually leads to neuronal
death (Goate and Hardy, 2012). Several published reports using
animal models have supported this amyloid cascade hypothesis
(Gotz et al., 2001; Lewis et al., 2001).ical Sciences, Department of
kodani, Kyotanabe-shi, Kyoto,
65 6135.
iyasaka).
Inc. This is an open access article uVarious anti-amyloid strategies have been developed, including
Ab immunization, antieAb-aggregation compounds, b- or g-
secretase inhibitors, and g-secretase modulators (Mangialasche
et al., 2010). Although some of these strategies were shown to be
effective in clearing the pre-existing Ab-aggregates and preventing
further Ab deposition and its associated toxicity, clinical studies
have reported that these strategies had at most limited efﬁcacy on
cognitive dysfunction of symptomatic patients (Corbett et al., 2012;
Holmes et al., 2008; Selkoe, 2012). In contrast, anti-tau therapy, if
any, could lead to clinical improvement in patients, as tau pathol-
ogies are closely linked to the levels of cognition in AD (Delacourte
et al., 1999; Gomez-Isla et al., 1997). In addition, as the tau pa-
thologies are associated with a number of age-related neurode-
generative diseases other than AD (Lee et al., 2001), anti-tau
therapy would have beneﬁcial effects on a broad spectrum of
dementias.
The mechanisms of tau-associated neurodegeneration still
remain unclear. Thus, current anti-tau strategies mostly target the
aggregation of tau, which is believed to be toxic to neurons
(Boutajangout et al., 2011). In fact, it is claimed that methylene blue,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinical symptoms (Wischik and Staff, 2009). However, it is not yet
known if aggregation or inclusion formation of tau is responsible
for the pathogenesis of tauopathies.
One way to efﬁciently screen for drugs is to test naturally
occurring compounds that have been validated epidemiologically.
Curcumin, a yellow phytochemical in the rhizome of Curcuma longa,
which has various biological effects (Belkacemi et al., 2011), has
been used as a spice in India. Epidemiological studies reported that
the prevalence of AD in India is less than that in the US, which may
suggest that a curcumin-rich diet might decrease the risk of
developing AD (Chandra et al., 2001). We thus hypothesized that
curcumin may attenuate tau-induced neurodegeneration.
In this study, we developed several Caenorhabditis elegans
models of tauopathy in which the neurons express human tau. We
observed tau-dependent neuronal dysfunction and morphological
abnormalities even in the absence of insoluble tau-aggregates.
Furthermore, curcumin is effective in treating the tau-induced
neuronal dysfunction.
2. Materials and methods
2.1. Development and maintenance of worm strains
Human tau, tau fragment, or DsRed complementary DNA (cDNA)
was subcloned downstream of the “pan-neuronal” unc-119 pro-
moter (Punc-119) sequence in the pFXneo-punc119 vector. For the
Punc-119-driven DsRed transgenic (Tg) worms, the expression
vector was diluted with the pBluescript vector and injected into
wild-type worm, N2. For the Punc-119-driven tau-Tg worms, the
vectors were coinjected into N2 with the marker pFX-Pges-
1:enhanced green ﬂuorescent protein. Germline transformation
and generation of genome-integrated Tg lines were performed us-
ing ultraviolet irradiation, as described previously (Mello and Fire,
1995; Mello et al., 1991; Mitani, 1995). The dose of radiation for
DNA integration was 250 J/m2 or 300 J/m2. The integrated Tg lines
were backcrossed to N2 5 (for tau) or 2 (for DsRed) times before
analysis. The Tg nematodes contained multiple copies of the
transgene. The Tg strains used are as follows; Mock-Tg (tmIs388),
WT4R-Tg (tmIs389 and tmIs390), WT3R-Tg (tmIs252), P301L-Tg
(tmIs227), R406W-Tg (tmIs226), 4R-tau C-terminal fragment-Tg
(CT4R, tmIs712), and DsRed-Tg (tmIs591) (Xie et al., 2014). For
morphological studies, the following tau-Tg lines that were cross-
bred with the DsRed-Tg line were used: Mock/DsRed-Tg (tmIs388/
591), WT4R/DsRed-Tg (tmIs390/591), and R406W/DsRed-Tg
(tmIs226/591). All the C. elegans strains were maintained on the
nematode growth medium (NGM)-containing plates that were
spread with Escherichia coli OP50 under standard conditions ac-
cording to Brenner withmodiﬁcations byWay and Chalﬁe (Brenner,
1974; Way and Chalﬁe, 1988).
2.2. Behavioral analyses
Healthy adult wormswere transferred to a newNGMplate to lay
eggs. Parent worms were picked off the plate 2 hours later, and the
resulting synchronized eggs were cultivated at 20 C until isolation.
For isolation, worms at varying stages were selected individually
and placed on new 3.5-cm plates. For the estimation of uncoordi-
nated movement (Unc), worms were observed under a microscope.
The severity of Unc was scored as follows: normal, wide bending
with fast movement; Unc, narrow bending with slow movement;
severe Unc, narrow bending with slower or negligible movement.
Liquid thrashing assays were performed as previously described
with minor modiﬁcations (Kraemer et al., 2003). The worms were
placed in a drop of M9 buffer (22-mM KH2PO4, 42-mM Na2HPO4,85-mM NaCl, 1-mM MgSO4) on a glass slide, and the thrashing
movements were counted for 30 seconds under a microscope. All
the assays were performed blindly. Twenty worms were used in
each assay for each experiment, and the experiment was performed
independently 3 to 4 times. Thus, 60 to 80 worms were assessed for
each line. The touch assay was performed as described previously
(Miyasaka et al., 2005a). The number of responses to 10 touch trials,
5 for the anterior and 5 for the posterior, were counted.
2.3. Biochemical analyses
Synchronized worms were harvested in M9 buffer and pelleted
by brief centrifugation. After washing with M9 buffer, the worm
pellets were weighed and stored at 80 C. For the preparation of
the total worm lysates, the pellets were sonicated in the sodium
dodecyl sulfate (SDS) sample buffer (80-mM Tris-HCl, 2% SDS, 10%
glycerol, 1% 2-mercaptoethanol, pH 6.8) and cleared by ultracen-
trifugation at 150,000 g for 10 minutes at 20 C. The SDS-soluble
fractions were used for Western blot analysis as described previ-
ously (Miyasaka et al., 2005b). The protein concentration for each
sample was normalized by Coomassie Brilliant Blue (Wako Pure
Chemical Industries, Ltd, Osaka, Japan) staining on SDS-
polyacrylamide gel electrophoresis gels. The detergent solubility
of tau was analyzed by sequential solubilization as described pre-
viously with minor modiﬁcations (Kraemer et al., 2003). Brieﬂy,
worm pellets were homogenized using a glass-teﬂon homogenizer
in high salt re-assembly buffer (RAB) (0.1-M 2-Morpholinoethane-
sulfonic acid, 0.5-mM MgSO4, 1-mM EGTA, 0.5-M NaCl, pH 6.8)
supplemented with protease and phosphatase inhibitors followed
by centrifugation at 3000 g for 3 minutes to remove the unho-
mogenized worms (Hasegawa et al., 1992; Miyasaka et al., 2005b).
The resulting supernatants were further centrifuged at 150,000 g
for 20 minutes, and the pellets were homogenized in radio-
immunoprecipitation assay (RIPA) buffer (50-mM Tris, 150-mM
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, pH 8.0) and centri-
fuged at 150,000 g for 20 minutes. The residual RIPA-insoluble
pellets were sonicated in the SDS sample buffer (RIPA-insoluble
fraction). The aliquots from the RAB- and RIPA-soluble supernatants
were mixed with the SDS sample buffer and used for Western blot
analysis. The microtubules and free tubulin were prepared as
described previously (Miyasaka et al., 2010). Brieﬂy, freshly har-
vested worms were homogenized in a buffer containing taxol and
Guanosine triphosphate and subjected to ultracentrifugation. The
supernatants and pellets, which consisted of free tubulin and
microtubule fractions, respectively, were analyzed by Western
blotting. For the absolute quantiﬁcation, worm tubulin and recom-
binant human tau (4-repeat 383-amino acid isoform) were puriﬁed
as described previously (Aamodt and Culotti, 1986; Aoyagi et al.,
2007).
2.4. Morphological analyses
For the morphological study, the tau/DsRed-Tg worms were
placed into a drop of M9 buffer containing 50-mM NaN3 on agar
pads and covered with a cover glass. For immunocytochemical
analysis, synchronized worms at various ages were harvested and
kept in 4% paraformaldehyde at 4 C for 24 hours. The ﬁxed worms
were dehydrated with 100% ethanol, immersed in 100% xylene, and
embedded in a parafﬁn block. Parafﬁn-embedded sections at a
6-mm thickness were processed using a microtome and placed onto
MAS-coated glass slides (Matsunami Glass Ind, Ltd, Osaka, Japan).
Deparafﬁnized and hydrated sections were dipped into the target
retrieval solution (DAKO, Glostrup, Denmark) at 95 C for 15
minutes and then blocked with 5% bovine serum albumin in tris-
buffered saline (TS; 50-mM tris-HCl, 150-mM NaCl, pH 7.6). The
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bodies in 1% bovine serum albumin in TS. After washingwith TS, the
bound antibodies were visualized using Alexa-conjugated second-
ary antibodies (Molecular Probes, Inc, Eugene, OR, USA). The spec-
imens were mounted with VECTASHIELD (Vector Laboratories, Inc,
Burlingame, CA, USA) and observed under a Zeiss Axioskop mi-
croscope equipped with the Lasersharp2000 software (Carl Zeiss
Inc, Thornwood, NY, USA).
2.5. Drug treatment
The chemical compounds were dissolved in the appropriate
solvents and stored at 20 C. For the drug administration, the
compounds were diluted in M9 buffer and directly spread onto an
NGM plate. The worms were synchronized and grown on the drug-
containing plates for 4 days and then analyzed. The sensitivities of
the worms to aldicarb and levamisole were assessed by the pro-
cedure described previously (Kraemer et al., 2003).
2.6. Antibodies and compounds
Anti-tauN and antieUNC-119N antibodies were raised against
the synthetic peptides AEPRQEFEVMEDHAGGC and QQSIAPG-
SATFPSQMPRGGC, respectively. These peptides were conjugated to
Keyhole limpet hemocyanin. The speciﬁc IgG was afﬁnitypuriﬁed
using antigenic peptides that were conjugated to activated thiol-
Sepharose 4B (GE healthcare Bio-Science KK, Tokyo, Japan) ac-
cording to the manufacturer’s instruction. Other antibodies used in
this studywerepool-2 (antiepan-tau, a generous gift fromDr.Mori),
DM1A (antiea-tubulin, Sigma-Aldrich, St. Louis, MO, USA), 1A4
(antiea-actin, Sigma), 6e11B1 (antieacetylated a-tubulin, Sigma),
6C5 (anti-GAPDH, Abcam, Cambridge, MA, USA), tau-1 (anti-
dephosphoSer199 and dephosphoSer202 tau, Chemicon, Temecula,
CA, USA), AT8 (anti-phosphoSer202 and phosphoSer205 tau, Inno-
genetics, Zwijndrecht, Belgium), AT100 (antiephosphoThr212 and
phosphoSer214 tau, Innogenetics), pS262 (anti-phosphoSer262 tau,
Invitrogen), paired helical ﬁlaments (PHF)-1 (anti-phosphoSer396
and phospho404 tau, a generous gift from Dr. Davies), MC-1
(conformation-dependent anti-tau, from Dr. Davies), and anti-
DsRed monoclonal and polyclonal antibodies (Clontech labora-
tories Inc, Mountain View, CA, USA). Other compounds used in this
study were purchased from Nacalai tesque, Inc (Kyoto, Japan).
3. Results
3.1. The generation of tau-transgenic worms
We previously reported that C. elegans is a useful tool for
studying neurodegenerative diseases, especially tauopathy. Using
the mec-7 promoter, we found that tau causes behavioral and
morphological abnormalities in the mechanosensory neurons. The
accumulation of tau, which is associated with neuritic abnormal-
ities, is preceded by the neuronal dysfunction (decreased touch
sensitivity) (Miyasaka et al., 2005a). This model system was useful
to correlate morphological abnormalities with neuronal functions,
but it was unsuitable for biochemical analysis. Thus, we generated
worm lines that expressed human tau in all the neurons that were
under the control of the unc-119 promoter (Fig. 1A; Maduro and
Pilgrim, 1995). We ﬁrst analyzed the expression pattern of tau us-
ing parafﬁn-embedded sections by immunocytochemistry. Tau was
present in the neurons in the nerve ring, ventral nerve cord, dorsal
nerve cord, lumbar ganglia, and thin neurites throughout the body,
but the expression levels of tau in the individual neurons appeared
to vary (Fig. 1B). This pan-neuronal expression pattern was similar
to the one that was previously reported (Maduro and Pilgrim,1995).To verify the expression of tau in each line, Western blot analysis
was performed on the total lysates of adult worms on the fourth day
after hatching. As shown in Fig. 1C, tmIs389 and tmIs390 expressed
low and high levels of the wild-type 4-repeat tau, respectively. The
amount of tau expressed in tmIs390 was approximately 3 times
higher than the levels in tmIs389. Similarly, the expression levels of
wild-type tau in tmIs252 were 4 times higher than the levels in
tmIs389. There were comparable levels of R406W tau in tmIs226
and wild-tau in tmIs389, and tmIs227 expressed P301L tau 7 times
more than wild-type tau in tmIs389 (Fig. 1C and D). The expression
levels of tubulin and glyceraldehyde-3-phosphate dehydrogenase
did not signiﬁcantly differ between the lines (Fig. 1C and D).
Because there is an extra 23 amino acids at the N-terminus of tau
that was derived from the 50-terminal sequence of unc-119, an
antieunc-119N antibody was raised against the synthetic peptide
corresponding to amino acids 7e23 of unc-119. This antibody was
used to label the proteins expressed in our system. Using this
antibody, we found that the tau expression levels in all the lines
used in this study were 3 to 5 times lower than the expression
levels of enhanced green ﬂuorescent protein in tmIs522 or DsRed in
tmIs591, which are the lines that showed no growth or behavioral
abnormalities (data not shown). The expression levels of tau
depended on the copy number of the vectors inserted into the
genome of the worm (data not shown). However, there was no
inhibition of unc-119 expression in any of the lines used in this
study. These results indicate that the abnormalities in the tau-Tg
worms were not caused by overexpression of nonspeciﬁc proteins
and the integration of the excess copies of unc-119 promoter. These
lines will be referred to as follows: Mock-Tg (tmIs388), WT4R(L)-Tg
(tmIs389), WT4R(H)-Tg (tmIs390), WT3R(H)-Tg (tmIs252),
R406W(L)-Tg (tmIs226), and P301L(H)-Tg (tmIs227).
3.2. Behavioral abnormality of tau-expressing worms
We did not observe premature mortality during development in
any of the Tg lines. However, behavioral abnormalities were present
in the WT4R(H)-Tg, WT3R(H)-Tg, R406W(L)-Tg, and P301L(H)-Tg
lines. The slower-moving worms left traces on the plate that were
narrower than the waves generated by the Mock-Tg or WT4R(L)-Tg
worms, although the severity varied among the individual worms.
The number of worms that were severely affected with the Unc
phenotype was the highest in the WT4R(H)-Tg and P301L(H)-Tg
lines and moderate in the WT3R(H)-Tg and R406W(L)-Tg lines
(Fig. 2A). These abnormalities appeared on the second day after
hatching (data not shown). We quantiﬁed the Unc phenotype by
the frequency of thrashing in a droplet of buffer (Fig. 2B). This liquid
thrashing analysis indicated that the frequency of thrashing in the
WT4R(H)-Tg, R406W-Tg(L), and P301L-Tg(H) lines was signiﬁcantly
lower than the frequencies in the Mock-Tg or WT4R(L)-Tg lines on
the second day after hatching. These abnormalities worsened on
the ﬁfth day after hatching. There was a signiﬁcant increase in the
frequency of thrashing in the WT3R(H) line on the second day after
hatching. The frequency of thrashing did not decrease in the Mock-
Tg and WT4R(L)-Tg lines throughout the experiment. Taken
together, we conclude that tau expression causes neuronal
dysfunction in the worms in a dose-dependent manner. Further-
more, by comparison with WT4R(L)-Tg line, the frontotemporal
dementia with parkinsonism-17 tau mutant (R406W) appeared to
enhance tau-induced neuronal dysfunction. The affected lines
exhibited a slight “dumpy” morphology resembling the unc-119
mutant strain (data not shown). In our C. elegans model, the
behavioral phenotype caused by the 3-repeat tau was not as severe
as the 4-repeat tau. In these lines, the 3-repeat and 4-repeat tau
proteins had comparable expression levels. The mean life spans of
the affected lines were slightly but signiﬁcantly shorter than the life
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Fig. 1. Pan-neuronal tau expression in Caenorhabditis elegans causes uncoordination. (A) Human tau cDNA encoding wild-type 0N4R (WT4R), wild-type 0N3R (WT3R), R406W
mutant 0N4R (R406W), or P301L mutant 0N4R (P301L) was expressed under the control of unc-119 promoter, which resulted in pan-neuronal expression in C. elegans. (B)
Immunocytolabeling of tau using pool2 revealed the expression of human tau in the cell body (arrow) and neurites (arrowheads) around the nerve ring and other neurons, including
the ventral nerve cord, dorsal nerve cord, and lumbar ganglia (not shown). The body wall is outlined by a dashed line. (C) Equal amounts of the total lysate from each worm line were
subjected to Western blotting using the anti-tau (pool2), antiea-tubulin (DM1A), and anti-GAPDH (6C5) antibodies. (D) The expression levels of tau (open bar; pool2) and a-tubulin
(closed bar; DM1A) are shown. The data represent the means  standard error of the protein amount in the worm pellet. Statistical signiﬁcance was evaluated using a 2-way ANOVA
followed by the Tukey/Kramer post hoc test. Abbreviations: ANOVA, analysis of variance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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expression and the phenotype in the P301L(H)-Tg line were un-
stable with passage, we used the Mock-Tg, WT4R(L)-Tg, WT4R(H)-
Tg, and R406W(L)-Tg lines for the further morphological and
pharmacological studies.
3.3. Biochemical characteristics of the tau expressed in worms
Tauopathy is deﬁned by the neurodegeneration associated with
intraneuronal aggregation of abnormally phosphorylated tau.Several animal models fulﬁlled these criteria. However, recent
ﬁndings questioned whether these biochemical abnormalities of
tau are required for neurodegeneration (Berger et al., 2007; Maeda
et al., 2006, 2007; Miyasaka et al., 2005a; Sahara et al., 2008;
Santacruz et al., 2005). Total lysates from the Mock-Tg and tau-Tg
lines were subjected to Western blotting using antiephospho-
tau-speciﬁc or antiedephospho-tau-speciﬁc antibodies. As shown
in Fig. 3A, all antiphospho-tau antibody used here labeled the tau
expressed in the worms. This ﬁnding indicates that exogenously
expressed tau even in the healthy WT4R(L)-Tg worms is highly
kDa
98.0
64.0
50.0
36.0
RIPA soluble RIPA insoluble
64.0
50.0
pool2
64.0
50.0
Tau-1
64.0
50.0
64.0
50.0
64.0
50.0
64.0
50.0
AT8
AT100
pS262
PHF-1
A
B RAB soluble
a b c d e f g a b c d e f gkDa kDa
b c d e f g b c d e f g b c d e f g
Fig. 3. Biochemical properties of tau in pan-neuronal tau-Tg worms. (A) The total
lysate from N2 (a), Mock-Tg (b), WT4R(L)-Tg (c), WT4R(H)-Tg (d), WT3R(H)-Tg (e),
R406W-Tg (f), or P301L-Tg (g) on the ﬁfth day after hatching was subjected to Western
blotting using phosphorylation-dependent and -independent anti-tau antibodies as
indicated. The serine and threonine residues examined here were phosphorylated to
similar extents. (B) RAB-soluble, RIPA-soluble, and RIPA-insoluble/SDS-soluble frac-
tions were subjected to Western blotting using the pool2 antibody. The RIPA-insoluble
tau was undetectable in each line even on the 18th day after hatching. Abbreviations:
RAB, re-assembly buffer; RIPA, radioimmunoprecipitation assay; SDS, sodium dodecyl
sulfate; Tg, transgenic.
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Fig. 2. Behavioral abnormalities of tau-Tg worms. (A) The numbers of healthy (white),
weak Unc (gray), and severe Unc (black) worms were counted on the ﬁfth day after
hatching as described in Section 2. The percent of the population for each phenotype is
given. (B) Thrashing in buffer for 30 sec for the indicated worms on the second (white
bar) and ﬁfth (black bar) day after hatching was counted. The data indicate the means
 standard error (n ¼ 56e60). The statistical signiﬁcance compared with Mock-Tg was
analyzed using the Tukey/Kramer test (#p < 0.01), and the indicated pairs were
analyzed using Student t test. Abbreviations: Tg, transgenic; Unc, uncoordinated
movement.
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found in PHF-tau. We next determined whether detergent-
insoluble tau accumulated in these lines. The lysates were
sequentially solubilized with RAB, RIPA, and SDS sample buffer.
Western blot analysis indicated that tau is soluble in our models on
the 10th day after hatching (data not shown) as well as the 18th day
after hatching, which is nearly at the end of the worm lifespan
(Fig. 3B). Dot blotting with MC-1 did not label tau in these worms
(data not shown). Thus, we conclude that in our worm models, tau
is phosphorylated to a high extent, but it does not form any insol-
uble aggregates.3.4. Morphological abnormalities in the neuron of the tau-Tg worms
We previously demonstrated that functionally affected, tau-
expressing mechanosensory neurons displayed neuritic abnor-
malities but not neuronal death (Miyasaka et al., 2005a). To explore
the morphological abnormalities in the neurons affected by tau
expression, the Mock-Tg and tau-Tg lines, including WT4R(L)-Tg,
WT4R(H)-Tg, and R406W(L)-Tg, were crossbred with the line
expressing DsRed in all the neurons (tmIs951). Although the
behavioral abnormalities seemed to be slightly more advanced inthe tau-Tg lines, the overall extent of severity was not altered in the
crossbred tau-Tg lines regardless of the presence of DsRed (data not
shown). The Mock/DsRed-Tg lines displayed no morphological ab-
normalities compared with the DsRed-Tg lines (Fig. 4A). However,
in the behaviorally affected worms, WT4R(H)/DsRed-Tg and
R406W(L)/DsRed-Tg, 2 thin neurites running along the body axis in
the caudal half showed abnormal morphologies, including kinks
and protrusions (Fig. 4CeE). Although the population was small,
similar neurites were observed in the aged WT4R(L)/DsRed-Tg
worms (Fig. 4B and E). One of the 2 neurites affected was identi-
ﬁed as ALN due to its localization relative to the cell body. Although
the other neurites were unable to be identiﬁed, immunocyto-
chemical analysis indicated that this neurite seemed to follow the
course of PLM, which can be labeled by the 6e11B1 antibody. In rare
cases, transversely oriented neurites running into protrusions were
found (data not shown). Although the precise origin of the pro-
trusions is unknown, it is possible that those are abnormally
enlarged spines. These morphological abnormalities of neurites
resemble the abnormalities found in aged worms (Tank et al., 2011;
Toth et al., 2012). The population of WT4R(L)/DsRed-Tg worms that
had kink neurites and protrusions was small but signiﬁcantly larger
than that population of the Mock/DsRed-Tg lines and gradually
became larger with age (Fig. 4G). The number of kink neurites was
larger in the behaviorally affected lines on the ﬁfth day after
hatching and continued to exist throughout life (Figs. 2 and 4G). In
the R406W(L)-Tg lines, the population of the worms that had kink
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WT3R (H)/DsRed-Tg (n = 20) 0.0003 0.0094
R406W (L)/DsRed-Tg (n = 19) < 0.0001 <0 .0001
P301L (H)/DsRed-Tg (n = 20) < 0.0001 < 0.0001
Mock/DsRed-Tg (n = 17) vs. kink (p) protrusion (p)
DsRed-Tg (n = 17) 0.6282 0.6715
WT4R (L)/DsRed-Tg (n = 19) < 0.0001 0.0057
WT4R (H)/DsRed-Tg (n = 17) < 0.0001 < 0.0001
WT3R (H)/DsRed-Tg (n = 20) 0.0005 0.0089
R406W (L)/DsRed-Tg (n = 20) 0.0005 < 0.0001
P301L (H)/DsRed-Tg (n = 16) 0.0009 0.0084
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Fig. 4. Age-dependent neuritic abnormalities in the tau-expressing worms. (AeF) CLSM images of thin neurites in the posterior part of the body are shown. Mock/DsRed-Tg (A),
WT4R(L)/DsRed-Tg (B and F),WT4R(H)/DsRed-Tg (C), R406W(L)/DsRed-Tg (D), and P301L(H)/DsRed-Tg (E) were observed under CLSM on the ﬁfth day (not shown),10th day (AeE), and
20th day (F) after hatching. Abnormal kinks (arrows) and protrusions (arrowheads) are indicated. Bars ¼ 10 mm. (G) The populations of the affected worms were quantiﬁed. Statistical
analysis was performed using the chi-squared test for independence compared to nonetau-Tg lines. Abbreviations: CLSM, confocal laser scanning microscopy; Tg, transgenic.
T. Miyasaka et al. / Neurobiology of Aging 39 (2016) 69e8174neurites decreased on the 20th day after hatching. This may be
caused by a loss of degenerating neurites (data not shown). The
frequencies of protrusions were moderate in the tau-Tg lines on theﬁfth day after hatching, but they signiﬁcantly increased with age
(Fig. 4G). Prospective observations of individual worms indicated
that the affected neurites gained more kinks and formed more
T. Miyasaka et al. / Neurobiology of Aging 39 (2016) 69e81 75protrusions until ﬁnally fragmentation occurred (data not shown).
Thus, the abnormal neurites in the tau-expressing worms likely
represent progressive neuronal degeneration.
3.5. Tau accumulation in the affected neurites
To determine whether tau accumulates in the affected neurites,
immunocytochemistry was performed on the parafﬁn-embedded
sections of the worms. As the DsRed ﬂuorescence was lost by the
parafﬁn-embedding process, whole neuronal morphology was
visualized with anti-DsRed antibodies. Double immunostaining for
tau and DsRed indicated that the relative amount of tau was higher
in the affected neurites than in the normal neurites (Fig. 5).
Furthermore, tau was concentrated at the turning point of the kink
neurites and protrusions (arrow and arrowheads in Fig. 5), but there
were no neuroﬁbrillary tangle-like inclusions. Thus, the morpho-
logical abnormalities in the neurites of the tau-Tg worms were
associated with tau accumulation.
3.6. Affected neurites are depleted of tubulin
Tauopathy-affected neurons were known to be devoid of mi-
crotubules or tubulin. This characteristic is conserved across various
animal models of tauopathy, including C. elegans (Miyasaka et al.,
2005a; Tatebayashi et al., 2002). We examined the levels of
tubulin in the neurites with tau accumulation. As shown in Fig. 6,
the affected thin neurites had less tubulin than did the intact
neurites. Furthermore, at the turning points of the kinks and pro-
trusions, the tubulin-stained area was thinner than in the other
portions of the affected neurites. Co-immunolabeling with tau and
tubulin clearly showed an inverse correlation between neurites that
had high and low tau expression (Fig. 6JeL). Together with the re-
sults in Fig. 5, it is possible that the amounts of tau and tubulin may
determine the fate of the neurons.
3.7. The effects of small chemical compounds on neuritic
abnormalities in the tau-Tg worms
The development of anti-tauopathy drugs is a major issue to be
studied. Chemical compounds were rigorously screened for their
potential to inhibit tau aggregation, and some compounds were
reported to improve tauopathy (Wischik and Staff, 2009). Although
many investigators have been involved in the screening for these
antiaggregation compounds, we cannot exclude the possibility that
compounds that do not have antiaggregation properties may
improve tauopathy. The C. elegans model of tauopathy is useful forA B
D E
G H
#
∗
Fig. 5. The localization of tau in the affected neurites. Parafﬁn-embedded sections of Mock
(A, D, and G) and pool2 (pan-tau) (B, E, and H) antibodies. The merged view is also shown (C
normal neurites (*). Tau was located in the abnormal swelling portions associated with kinsuch chemical screenings because of the easy application of com-
pounds and expansion of scale, as well as rapid evaluation of
neuronal function. Curcumin is a yellow-colored chemical com-
pound puriﬁed from the root of C. longa, a turmeric spice. In vitro
and in vivo studies indicate that curcumin prevented Ab aggrega-
tion and reduced the extent of Ab deposition and cognitive
dysfunction of APP (amyloid precursor protein)-Tg mice (Begum
et al., 2008; Lim et al., 2001; Ma et al., 2009; Ono et al., 2004;
Yang et al., 2005). Curcumin has a wide variety of biological ef-
fects, including antioxidant, anti-inﬂammatory, and anticancer ac-
tivities (Belkacemi et al., 2011). The antagonizing effects of
curcumin on Ab aggregation could account for its beneﬁcial effects
on APP-Tg animals. However, it is possible that other functions of
curcumin may be responsible for the protection against AD.
The tau-Tg worms were grown on a plate supplemented with
curcumin and analyzed their behavior. As shown in Fig. 7A and B,
the WT4R(H)-Tg lines showed a severe Unc phenotype on plates
containing either the vehicle or low-dose (10 mg/plate; 3 mM) cur-
cumin. However, high doses (100 mg/plate; 30 mM) of curcumin
signiﬁcantly reduced the proportion of severely affected worms
compared with the vehicle-treated worms. Curcumin was also
effective in treating the behavioral abnormalities and the low liquid
thrashing in the mutant tau-expressing worms (Fig. 7B and
Supplementary Fig. 2). Curcumin treatment did not affect the
expression of tau, but it did slightly reduce the expression of a-
tubulin (Fig. 8 and data not shown). Similarly, curcumin treatment
did not affect tau phosphorylation (Fig. 8). The curcumin-treated
worms were slightly smaller than the vehicle-treated worms
(data not shown). Thus, curcumin suppressed neuronal dysfunction
by inhibiting the mechanisms downstream of a pivotal step shared
by the wild-type and mutant tau. We further analyzed other pre-
viously reported compounds, such as methylene blue, resveratrol,
and trehalose (Tanaka et al., 2004; Wang et al., 2006; Wischik et al.,
1996). High doses (200 mM) of methylene blue ameliorated the
behavioral abnormalities in the tau-expressing worms. However,
the other compounds did not improve neuronal dysfunction in the
Tg worms (data not shown).3.8. Curcumin improved neuritic abnormalities in the tau-Tg worms
We further examined the effects of curcumin on morphological
abnormalities in the tau-Tg worms. To quantify these abnormalities,
we counted the kinks and protrusions along a 200-mm length of the
neurites in the caudal half. This length spans most of the high-
lighted neurites. As shown in Fig. 9, curcumin signiﬁcantly reduced
the number of kinks in the affected neurites in both the WT4R(H)-C
F
I
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-Tg (AeC) and R406W(L)-Tg worms (DeI) were colabeled with anti-DsRed monoclonal
, F, and I). Tau was more intensely labeled in the affected neurites (#) compared to the
ks (arrows) and protrusions (arrowheads). Bar ¼ 10 mm. Abbreviation: Tg, transgenic.
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Fig. 6. The localization of tubulin in affected neurites. Parafﬁn-embedded sections of Mock-Tg (AeC) and R406W(L)-Tg worms (DeL) were colabeled with rabbit anti-DsRed
polyclonal (A and D) and DM1A (a-tubulin; B and E), or pool2 (G and J), and DM1A antibodies (H and K). Merged views are shown (C, F, I, and L). The area of tubulin staining
is thinner in the affected neurites (#) than in the normal neurites (*). The artifact due to specimen wrinkling is indicated by ({). Tubulin is absent in abnormally swelling portions
associated with kinks (G and H; arrows) and protrusions (arrowheads in inset). Bar ¼ 10 mm. Abbreviation: Tg, transgenic.
T. Miyasaka et al. / Neurobiology of Aging 39 (2016) 69e8176Tg and R406W(L)-Tg lines (Fig. 8A and B). The number of pro-
trusions in the same neurites was also signiﬁcantly decreased by
the curcumin treatment (Fig. 8A and C). Taken together, curcumin
improves not only neuronal dysfunction but also morphological
abnormalities in the tau-Tg worms.0
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Fig. 7. Curcumin improves behavioral abnormalities in wild-type and mutant tau-
expressing worms. (A) Nonetau-Tg, WT4R(H)-Tg, and R406W(L)-Tg worms were
grown on NGM plates supplemented with or without curcumin for 3 days and sub-
jected to behavioral analysis. The data show the populations of healthy (open bar),
weak Unc (hatched bar), and severe Unc (closed bar) worms (n ¼ 60e100) in each line.
(B) The averaged populations (means  standard error) of total Unc worms from 3 to
5 independent experiments are shown. High doses of curcumin signiﬁcantly improved
the behavioral abnormalities in mutant tau-expressing worms. The statistical
signiﬁcance within each transgenic line was analyzed using the Tukey/Kramer test.
Abbreviations: NGM, nematode growth media; Tg, transgenic; Unc, uncoordinated
movement.3.9. Curcumin increased the levels of acetylated a-tubulin
Cumulative lines of evidence indicate that curcumin affects the
cytoskeletal organization in neurites. A biochemical analysis of
microtubules in the Tg worms was performed. The microtubules
and free tubulin in the worms were fractionated, but there was no
difference in the amount of microtubule-forming tubulin between
the vehicle- and curcumin-treated animals (Fig. 10A). However, the
amount of acetylated a-tubulin in the microtubule fraction was
signiﬁcantly increased in the curcumin-treatedworms (Fig.10A and
B). As the acetylation of a-tubulin occurs in association with
microtubule stabilization, it is possible that curcumin enhances
microtubule stability in neurons. Most of the expressed tau that
does not bind to microtubules is likely hyperphosphorylated
(Fig. 10A). MEC-12, an a-tubulin isoform, can be acetylated and is
expressed in the mechanosensory neurons in C. elegans, which are
involved in the escape response from gentle body touch (Fukushige
et al., 1999). To assess whether the acetylation of MEC-12 is asso-
ciated with neuronal function, touch sensitivity was evaluated in
curcumin-treated animals. The WT4R(H)-Tg line displayed abnor-
malities toward the touch sense that could be discriminated from
the Unc phenotype (Fig. 10C). Curcumin treatment improved the
dysfunction of the touch neurons, and this improvement could
presumably be related to MEC-12 acetylation. These data suggest
that curcumin protects neurons from tauopathy via microtubule
stabilization.3.10. Curcumin ameliorated the behavioral abnormalities in tau
fragment-expressing worms
Tau fragments that consist of the microtubule-binding domain
are highly prone to aggregation (Fatouros et al., 2012; Wang et al.,
2009). Consistent with the previous study, the worms expressing
C-terminal fragments of 4-repeat tau showed severe behavioral
abnormalities and contained dimers that were stable in SDS (Fig.11;
Xie et al., 2014). To determine whether curcumin affected tau
oligomer formation, the worms expressing the tau fragments were
fed curcumin. High doses of curcumin reduced the population of
worms displaying the severe Unc phenotype. However, curcumin
did not have an effect on the formation of tau-fragment dimers.
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Fig. 8. Curcumin has no effect on tau phosphorylation. (A) Total lysates from nonetau-Tg (Mock), WT4R(H), and R406W(L) lines with or without curcumin treatment were subjected
to Western blotting using the indicated antibodies. The band intensities of AT100 (B), AT8 (C), AT180 (D), pS262 (E), and PHF-1 (F) are normalized to total tau (pool2). The statistical
analyses were performed using Welch’s t-test. Abbreviation: Tg, transgenic.
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a manner that is independent of tau aggregation.
4. Discussion
In this study, we developed new lines of tau-expressing
C. elegans that exhibit behavioral abnormalities in a dose- and
mutation-dependent manner. In these models, tau is phosphory-
lated on many sites similar to those that were identiﬁed in PHF-tau.
Hyperphosphorylation of tau occurred even in seemingly healthy
worms, but none of the lines developed detergent-insoluble ag-
gregates. The behaviorally affected worms were associated with
progressive neuritic abnormalities and loss of microtubules
accompanied by tau accumulation.We further report that curcumin
can suppress both the behavioral and morphological abnormalities.
Finally, microtubule stabilization, rather than aggregation inhibi-
tion, likely accounts for the beneﬁcial effects of curcumin.
It is unknown how neuronal dysfunction in tauopathy is caused.
Previous evidence suggests that the formation of pathological in-
clusions, such as neuroﬁbrillary tangles, may not necessarily be
required for neuronal death but may instead represent a protective
measure of the neuron (Berger et al., 2007). Besides our tau-Tg
worm models, Spittaels et al. (1999) examined a mouse model
overexpressing 4-repeat human tau and found that axonal degen-
eration was raised without neuroﬁbrillary tangle formation, sug-
gesting that there may be similar mechanisms of tau toxicity inworms and mice. At present, oligomers or small, soluble aggregates
of tau are the proposed cause of toxicity, but this assumption re-
mains controversial (Berger et al., 2007; Maeda et al., 2006, 2007;
Sahara et al., 2008). Conversely, it has been reported that tau
deﬁciency rescues neuronal dysfunction that is induced by the
overexpression of APP (Ittner et al., 2010; Roberson et al., 2007,
2011). This suggests that tau toxicity may be mediated by some-
thing other than aggregation. What is known at present is that the
propensity for tau aggregation may be linked, presumably in an
indirect way, to tau-mediated toxicity.
Even soluble monomeric tau resulted in toxicity in our worm
models; however, we cannot completely exclude the possibility of
minute levels of soluble toxic oligomers. In the nematode model of
tauopathy presented in this study, no insoluble aggregates were
found in the affected worms, even at the later stages of life. This is
not consistent with a previous model and may be caused by dif-
ferences in the promoter sequences that were used. Another
possible explanation for this difference is that the tau-expression
levels were different. We failed to detect conformationally
abnormal tau with the MC-1 antibody (data not shown; Jicha et al.,
1997). Nevertheless, tau was phosphorylated at the sites identiﬁed
in PHF-tau, which aggregates in the brains of AD and
frontotemporal dementia with parkinsonism-17 patients, and was
not bound to microtubules (Miyasaka et al., 2001a, 2001b;
Morishima-Kawashima et al., 1995; Yoshida and Ihara, 1993). A
panel of antiephospho-tau speciﬁc antibodies was unable to
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Fig. 9. Curcumin improves neuritic abnormalities in tau-expressing worms. (A) The ﬂuorescence of DsRed expressed in the neurons of Mock-Tg worm (A and B), WT4R(H)-Tg (C and
D), and R406W(L)-Tg (E and F) without (A, C, and E) or with 30 mM of curcumin treatment (B, D, and F) for 10 days are shown. Abnormal kinks (G) and protrusions (H) in vehicle-
(closed bar) or curcumin- (open bar) treated animals were quantiﬁed. The data represent the mean counts of kinks and protrusions along 200 mm of the affected neurites  standard
error (n ¼ 22e43 animals). The statistical signiﬁcance between vehicle- and curcumin-treated animals within each Tg line were analyzed using Welch’s t-test. Abbreviation: Tg,
transgenic.
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affected worms. Thus, hyperphosphorylation may not be sufﬁcient
for tau aggregation. We previously reported that tau is liberated
from the microtubules and subsequently hyperphosphorylated
(Miyasaka et al., 2010). Taken together, it is possible that the
microtubule-unbound tau, which is susceptible to phosphorylation,
could trigger neuronal dysfunction in tauopathy.
Neuritic abnormalities consist of loss of tubulin (microtubules),
and tau accumulation (Cash et al., 2003; Gray et al., 1987; Paula-
Barbosa et al., 1987). Other C. elegans models and various in vivo
models of tauopathy also share these characteristics (Miyasaka
et al., 2005a; Tatebayashi et al., 2002). Previously, it has been re-
ported that acute tau phosphorylation does not induce microtubule
destruction (Planel et al., 2008). Conversely, microtubule destruc-
tion induces tau liberation and the subsequent phosphorylation
(Miyasaka et al., 2010). Thus, massive microtubule degeneration
may occur in the comparatively early stage of the cascade of tau-
opathy. Related to this, it would be reasonable to postulate that the
formation of detergent-insoluble aggregate of tau occurs in the late
stage of soluble tau accumulation.
Although various mammalian models have provided important
insight into the detailed mechanisms of tauopathy, it is not possible
to use these models for large-scale drug screening. In contrast,
invertebrate models can be used for the rapid screening of small
compounds. C. elegans is widely used for basic biological studies,
especially large scale genetic screens for behavioral and morpho-
logical abnormalities (Fraser et al., 2000). This characteristic
prompted us to use this model to screen drugs that would treat
neurodegenerative diseases. In this study, we were able to evaluate
the anti-tauopathy effect of various compounds within a few days.
This may be the shortest time period for in vivo analyses and sug-
gests the feasibility of this model for strategic drug screening. Using
this in vivo model provides an opportunity to discover new
candidate compounds that are involved in as-yet unidentiﬁed stepsto the tau-induced neuronal dysfunction. This unbiased systemmay
also provide new insights into the disease mechanism as well as
new drug targets against tauopathy.
One important question is whether a compound that is effective
in the worm model is also effective in the mouse model. If so, the
disease mechanism may be the same in both species. In particular,
we believe that a mechanism other than aggregate formation may
cause tauopathy. Curcumin was administered to P301L mice from
20 to 23 months of age. Preliminary observations indicate that
curcumin reduces the number of tau-accumulated neurons and
improves the neuritic abnormalities in the brain (article in prepa-
ration). Ma et al. (2013) also reported that the curcumin reduced
soluble tau and behavioral abnormalities in tau-Tg mice, possibly
through the elevation of heat shock proteins. Although there are
various views on the mechanism, curcumin is effective in treating
tauopathy in several preclinical models.
There are limitations with the worm models; compounds that
do not penetrate the cuticle are excluded from the screening.
However, the mutants of acs-20 and acs-22 genes that are defective
in the cuticle barrier could allow for the penetration of small
molecules into the worms (Kage-Nakadai et al., 2010). The appli-
cation of these mutants as disease models would be highly prom-
ising to extend the use of the C. elegans model for drug screening.
The beneﬁts of this model system over other models, such as easy
handling and rapid screening, are signiﬁcant.
We note that trehalose, which is an inducer of autophagy and a
chemical chaperon had no protective effects on our tau-Tg worms.
These results may be explained by the lack of insoluble aggrega-
tions in the tau-Tg worms. Also, the lower dose used here may be
another reason for the negative results. As a suppressor of nema-
tode aging, over 100-fold higher trehalose doses were used in a
previous study (Honda et al., 2010).
Curcumin improves tau-induced neuronal dysfunction and
neuritic abnormalities in the C. elegans model of tauopathy. This
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(C) Touch sense abnormalities in the tau-expressing worms were improved by the
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T. Miyasaka et al. / Neurobiology of Aging 39 (2016) 69e81 79indicates that curcumin is a strong candidate for an anti-tauopathy
drug. Curcumin is already known to suppress Ab aggregation, and
its effectiveness was conﬁrmed using Tg mouse models, although
recently conducted phase II trials in patients with mild cognitive
impairment and AD were reported to have failed. This failure may
be partially due to low bioavailability (Ringman et al., 2012). In this
study, we show that curcumin is also effective to treat tauopathy.
Surprisingly, curcumin did not suppress tau phosphorylation or
aggregation, but it did protect the worms from neuritic and cyto-
skeletal abnormalities. Although the pharmacological targets ofcurcumin are not identiﬁed, increased levels of acetylated a-tubulin
suggest that microtubule stabilization is involved, either directly or
indirectly. Kraemer et al. (2006) reported many genetic modiﬁers of
Unc movement in a tau-Tg worm model, including chaperones,
phosphatases, and kinases, some of which may inﬂuence micro-
tubule stabilization, raising several possible candidate targets of
curcumin. Curcumin has been reported to induce Skn-1/Nrf2
pathway, which has a crucial role in maintaining cellular redox
homeostasis. (Jimenez-Osorio et al., 2015). Thus, it is possible that
the skn-1/Nrf2 pathway was involved in the anti-tauopathy effect
of curcumin, because the Nrf2 activation presumably rescued tau-
opathy inmousemodel (Stack et al., 2014). It can be considered that
the unidentiﬁed factors underlying skn-1/Nrf2 pathwaymay have a
potential to protect the neurodegeneration due to tauopathy
through the stabilization of microtubules.
Microtubule destruction is the central event that occurs in
neurons affected by tau and should be targeted to treat tauopathy.
Recent reports indicate that microtubule stabilizers can improve
tauopathy, which is consistent with the effectiveness of curcumin in
tau-Tg worms (Barten et al., 2012; Brunden et al., 2010, 2012;
Matsuoka et al., 2007, 2008; Shiryaev et al., 2009; Zhang et al.,
2012). A recent study showing that curcumin extends the lifespan
of C. elegans by maintaining protein homeostasis strongly supports
the view that curcumin stabilizes tubulin or microtubules in
T. Miyasaka et al. / Neurobiology of Aging 39 (2016) 69e8180neurons (Alavez et al., 2011). We are currently trying at the
screening of curcumin derivatives that have enhanced bioavail-
ability and stabilize microtubules and are effective against
tauopathy.
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